1.
Study characteristics
| Author (year) | Country | Study design | Treatment | Sample size (n) | Age (years) | Gender | |||||||
| Total | cTACE | TARE
(90Y) |
cTACE | TARE
(90Y) |
cTACE | TARE (90Y) | |||||||
| Male | Female | Male | Female | ||||||||||
| RCT: Randomized controlled trial; NA: Negative available | |||||||||||||
| Soydal et al.13 | Turkey | Observational studies | cTACE /
TARE (90Y) |
80 | 40 | 40 | 66.15±7.81 | 62.28±9.73 | 34 | 6 | 33 | 7 | |
| Salem et al.14 | USA | RCT | cTACE /
TARE (90Y) |
45 | 21 | 24 | 64
(62–70) |
62
(58–65) |
16 | 5 | 17 | 7 | |
| Kolligs et al.15 | Germany+
Spain |
RCT | cTACE /
TARE (90Y) |
28 | 15 | 13 | 66.7±9.04 | 65.8±6.73 | 13 | 2 | 11 | 2 | |
| El Fouly
et al.16 |
Germany+
Eygpt |
Observational studies | cTACE /
TARE (90Y) |
86 | 42 | 44 | 58.3±6.7 | 66.1±8.9 | 38 | 4 | 36 | 8 | |
| She et al.17 | China | Observational studies | cTACE /
TARE (90Y) |
32 | 16 | 16 | 62.5
(48–78) |
55
(37–73) |
13 | 3 | 15 | 1 | |
| Moreno-Luna
et al.18 |
USA | Observational studies | cTACE /
TARE (90Y) |
116 | 55 | 61 | 66
(46–84) |
64
(29–88) |
43 | 12 | 49 | 12 | |
| Salem et al.19 | USA | Observational studies | cTACE /
TARE (90Y) |
245 | 122 | 123 | 61
(33–38) |
66
(30–38) |
102 | 20 | 87 | 36 | |
| Lance et al.20 | USA | Observational studies | cTACE /
TARE (90Y) |
73 | 35 | 38 | 61
(51–84) |
63
(44–85) |
28 | 7 | 33 | 5 | |
| Kooby et al.21 | USA | Observational studies | cTACE /
TARE (90Y) |
790 | 691 | 99 | NA | NA | 518 | 173 | 70 | 29 | |
| Carr et al.22 | USA | Observational studies | cTACE /
TARE (90Y) |
71 | 44 | 27 | 61.0±9.9 | 58.7±10.8 | 36 | 8 | 23 | 4 | |
| Lewandowski
et al.23 |
USA | Observational studies | cTACE /
TARE (90Y) |
86 | 43 | 43 | 65
(58.9–67.8) |
68
(62.8–75) |
36 | 7 | 38 | 5 | |